Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

5.24

Today's Change

0.00 (0.00%)

Day's Change

5.18 - 5.31

Trading Volume

450,126

Overview

Market Cap

1 Billion

Shares Outstanding

311 Million

Avg Volume

1,184,004

Avg Price (50 Days)

3.97

Avg Price (200 Days)

2.42

PE Ratio

-43.67

EPS

-0.12

Earnings Announcement

21-Aug-2024

Previous Close

5.24

Open

5.24

Day's Range

5.18 - 5.31

Year Range

0.675 - 5.67

Trading Volume

450,126

Price Change Highlight

1 Day Change

0.00%

5 Day Change

-2.24%

1 Month Change

26.57%

3 Month Change

95.52%

6 Month Change

204.65%

Ytd Change

149.52%

1 Year Change

596.20%

3 Year Change

249.33%

5 Year Change

249.33%

10 Year Change

249.33%

Max Change

249.33%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment